Results 31 to 40 of about 2,055,373 (247)

Pharmacology and pharmacovigilance of protein kinase inhibitors

Therapies, 2022
Protein kinase inhibitors experienced their advent in the 2000s. Their market introduction made it possible to constitute a class of targeted therapies administered orally. This name was chosen to mark a break with conventional chemotherapy drugs, but it is important to stress that these are multi-target drugs with complex affinity profiles.
Khouri, Charles, Mahé, Julien, Caquelin, Laura, Locher, Clara, Despas, Fabien   +4 more
openaire   +5 more sources

Analysis of the phosphoproteome of CK2α(–/–)/Δα′ C2C12 myoblasts compared to the wild-type cells

Open Biology, 2023
CK2 is a Ser/Thr protein kinase composed of two catalytic (α/α′) subunits and a non-catalytic β-subunit dimer, whose activity is often abnormally high in cancer cells.
Christian Borgo, Luca Cesaro, Tsuyoshi Hirota, Keiko Kuwata, Claudio D'Amore, Thomas Ruppert, Renata Blatnik, Mauro Salvi, Lorenzo A. Pinna   +8 more
doaj   +1 more source

Computerized Protein Modeling and Molecular Docking Analysis of Human Proto Oncogene Tyrosine Protein Kinase YES for Discovery of Novel Lead Molecules [PDF]

, 2010
Human proto-oncogene tyrosine-protein kinase YES (YES) is a non receptor kinase belongs to Src family. This gene lies in close proximity to thymidylate synthase gene on chromosome 18, and a corresponding pseudogene has been found on chromosome 22.
Amineni Umamaheswari, Dibyabhaba Pradhan, Karuna J. Jaya Sai   +2 more
core   +2 more sources

Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells

Scientific Reports, 2022
Therapeutic resistance to kinase inhibitors constitutes a major unresolved clinical challenge in cancer and especially in glioblastoma. Multi-kinase inhibitors may be used for simultaneous targeting of multiple target kinases and thereby potentially ...
Oxana V. Denisova, Joni Merisaari, Amanpreet Kaur, Laxman Yetukuri, Mikael Jumppanen, Carina von Schantz-Fant, Michael Ohlmeyer, Krister Wennerberg, Tero Aittokallio, Mikko Taipale, Jukka Westermarck   +10 more
doaj   +1 more source

Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells [PDF]

, 2015
Medullary thyroid cancer (MTC) is an aggressive malignancy responsible for up to 14% of all thyroid cancer-related deaths. It is characterized by point mutations in the rearranged during transfection (RET) proto-oncogene.
Barollo, Susi, Bertazza, Loris, Boscaro, Marco, Cavedon, Elisabetta, Faggian, Diego, Mian, Caterina, Pelizzo, MARIA ROSA, Pezzani, Raffaele, Plebani, Mario, Radu, CLAUDIA-MARIA, Rubin, Beatrice, Simioni, Paolo   +11 more
core   +1 more source

A comprehensive review of protein kinase inhibitors for cancer therapy

Expert Review of Anticancer Therapy, 2018
Introduction: Protein kinases are involved in various cellular functions. About 2% of the human genome encodes for protein kinases. Dysregulation of protein kinases is implicated in various processes of carcinogenesis.
Radhamani Kannaiyan, D. Mahadevan
semanticscholar   +1 more source

Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome. [PDF]

PLoS ONE, 2017
Protein kinases are critical drug targets for treating a large variety of human diseases. Type-III kinase inhibitors have attracted increasing attention as highly selective therapeutics.
Zheng Zhao, Lei Xie, Philip E Bourne
doaj   +1 more source

JNK signalling in cancer: In need of new, smarter therapeutic targets [PDF]

, 2013
Copyright © 2013 The British Pharmacological Society. This is the accepted version of the following article: Bubici, C. and Papa, S. (2014), JNK signalling in cancer: in need of new, smarter therapeutic targets.
Adams, Ahmed, Anbalagan, Annunziata, Antonyak, Bain, Barbarulo, Barr, Behrens, Bennett, Bharti, Bogoyevitch, Bogoyevitch, Borsello, Bost, Carboni, Cazanave, Cellurale, Cellurale, Cellurale, Chang, Chang, Chauhan, Chen, Chen, Chen, Chen-Deutsch, Cho, Choi, Chromik, Cilloni, Cripe, Cui, Cui, Das, Davis, Deininger, Dérijard, Eferl, Estey, Farazi, Ferrandi, Finegan, Fuchs, Gaillard, Gao, Gao, Gilmore, Goenka, Graff, Gururajan, Hagiwara, He, Heo, Hess, Hideshima, Hideshima, Hideshima, Hirosumi, Ho, Huang, Hui, Hunot, Jaeschke, Jagtap, Jemal, Johnson, Kamenecka, Kaneto, Kaoud, Ke, Keats, Kersting, Kuan, Kuperwasser, Li, Llovet, Lloyd, LoGrasso, Luedde, Maclean, Maeda, Mamay, Manning, Manning, Min, Mucha, Murati, Nagata, Nateri, Ngoei, Ngoei, Nitta, Oleinik, Owens, Papa, Papa, Plantevin Krenitsky, Qiu, Raitano, Reinecke, Ricard, Rodrigues, Ronaldson, Roy, Sabapathy, Sakurai, Schramek, Seki, She, Siddiqui, Smeal, Srivastava, Stebbins, Su, Su, Szczepankiewicz, Takahashi, Tong, Tournier, Tsuiki, Waetzig, Wagner, Wang, Wang, Webster, Whitmarsh, Whitmarsh, Yamamoto, Yan, Yang, Yao, Yoon, Yoshida, Zhang, Zhang, Zhang, Zhang   +137 more
core   +2 more sources

Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study

European Respiratory Journal, 2019
The pathophysiology of pulmonary arterial hypertension (PAH) induced by protein kinase inhibitors (PKIs) remains unclear. To gain knowledge into this rare and severe pathology we performed a study combining a pharmacovigilance approach and the ...
Lucie Cornet, C. Khouri, M. Roustit, C. Guignabert, M. Chaumais, M. Humbert, B. Revol, F. Despas, D. Montani, J. Cracowski   +9 more
semanticscholar   +1 more source

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

BMC Medicine, 2012
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial Parkinson's disease (PD). Variation around the LRRK2 locus also contributes to the risk of sporadic PD.
Rudenko Iakov N, Chia Ruth, Cookson Mark R   +2 more
doaj   +1 more source